Category: MedtronicSyndicate content

Medtronic launches new spine devices

May 5, 2015 by Mark Hollmer

Medtronic rolls out a new spinal prosthesis device and gains FDA clearance for an anterior cervical plate system.

Medtronic launches new spine devices

Medtronic (NYSE:MDT) said it gained 510(k) clearance for 1 spinal repair device and began the commercial rollout of another.

FDA clears Medtronic's Euphora balloon

May 5, 2015 by Brad Perriello

The FDA grants 510(k) clearance to Medtronic for its Euphora semicompliant balloon dilation catheter for coronary stenting procedures.

FDA clears Medtronic's Euphora balloon

Medtronic (NYSE:MDT) today said the FDA cleared its Euphora semicompliant balloon dilation catheter, and the company wasted no time in getting the pre-stenting device on the U.S. market.

FDA expands indication for Medtronic's StealthStation nav suite

May 4, 2015 by Brad Perriello

Medtronic says the FDA expanded the indication for its StealthStation surgical navigation tool to include cranial and ENT procedures in children and adults.

FDA expands indication for Medtronic's StealthStation nav suite

Globus: Synthes witness faked CV | Medtech legal news for the week of May 4, 2015

May 4, 2015 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Witness for J&J's Synthes faked credentials; Medtronic agrees to stop making SynchroMed drug pump; NuVasive settles Justice Dept. probe for $14m; Boston Scientific inks $119m pelvic mesh deal; Stryker inks $3m settlement in Howmedica reimbursement suit

Globus: Witness for J&J's Synthes faked credentials

April 28, 2015 by Brad Perriello

Medtronic: Strong data from real-world Endurant AAA stent graft registry

April 30, 2015 by Mark Hollmer

A new analysis of more than 1,200 patients treated with Medtronic's Endurant AAA stent graft showed 'strong results' in short- and standard-neck abdominal aortic aneurysms.

Medtronic: Strong data from real-world Endurant AAA stent graft registry

Renal denervation: Medtronic launches afib trial

April 30, 2015 by Brad Perriello

Medtronic says it's launching a clinical trial evaluating renal denervation and cardiac ablation in treating atrial fibrillation.

Renal denervation: Medtronic launches afib trial

Medtronic (NYSE:MDT) today said it's launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.

FDA panel on aneurysm devices | Regulatory news for the week of April 27, 2015

April 28, 2015 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: FDA panel issues aneurysm device recommendations; Burr introduces fast-track FDA bill; Medtronic wins EU approval for MRI-safe Activa DBS devices; FDA approves Siemens 3D breast tomo device; Maquet's TigerPaw II recall is Class I

FDA panel issues aneurysm device recommendations

April 21, 2015 by Brad Perriello